Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

Table 3

Association between KRAS status and efficacy in PACCE and CAIRO2.

	Response rate, %		Progression-free survival, mo		Overall survival, mo
	Wild-type	Mutant	Wild-type	Mutant	Wild-type	Mutant
	KRAS	KRAS	KRAS	KRAS	KRAS	KRAS
PACCE oxaliplatin cohort [43] (𝑁=664)
Ox + Bev + Pmab	50	47	9.8	10.4	20.7	19.3
Ox + Bev	56	44	11.5	11.0	24.5	19.3
CAIRO2 [47] (𝑁=528)
Cap, Ox + Bev + Cmab	61.4	45.9	10.5	8.1	21.8	17.2
Cap, Ox + Bev	50.0	59.2	10.6	12.5	22.4	24.9

Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; NR: not reported; Ox: oxaliplatin; PACCE: Panitumumab Advanced Colorectal Cancer Evaluation; Pmab: panitumumab.